InvestorsHub Logo
Followers 31
Posts 2649
Boards Moderated 0
Alias Born 10/28/2013

Re: Extremist223 post# 98526

Friday, 01/27/2017 10:08:45 AM

Friday, January 27, 2017 10:08:45 AM

Post# of 703770
"Mesencyhmals are doing better because they have more mutations and more targets compared to the other groups."

What doesn't make sense about that is that there are presumably scores if not hundreds of neo-antigens in every tumor type and DCVax-L presumably targets all of them. This is the model we have. Unless they have a new model... I suspect the difference has more to do with blockade function.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News